Merck Sharp + Dohme Corp.

Merck Canada Inc.

Ronald K Chang

Scott D Kuduk

John A McCauley

Michael W Miller

Jack D Scott

Ling Tong

Thomas J Greshock

Christina Di Marco

Xing Dai

Peter D Williams

Philippe G Nantermet

Oscar Miguel Moradei

Hong Liu

Duane E DeMong

Jason W Skudlarek

Izzat Tiedje Raheem

Christopher James Bungard

William D Shipe

David Jonathan Bennett

Christian Beaulieu

Vouy Linh Truong

Kallol Basu

Catherine M Wiscount

Carmela Molinaro

Sheldon N Crane

Satyanarayana Tummanapalli

Zheng Tan

Jesse J Manikowski

Wei Li

Jeffrey W Schubert

Daniel Mckay

Christian Nadeau

Sivalenka Vijayasaradhi

Sanjay Kumar Singh

Kate Holloway

Li Hao

John A Mccauley

Michael Miller

Christopher Douglas Cox

Andrew J Cooke

Tummanapalli Satyanarayana

Christina Ng Di Marco

The present invention is directed to azaindazole compounds which are potent inhibitors of LRRK2 kinase and useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Compounds inhibiting leucine-rich repeat kinase enzyme activity

The compounds encompassed by Formula I include compounds which are HIV protease inhibitors and other compounds which can be metabolized in vivo to HIV protease inhibitors. The compounds and their pharmaceutically acceptable salts are useful for the prophylaxis or treatment of infection by HIV and the prophylaxis, treatment, or delay in the onset of AIDS. The compounds and their salts can be employed as ingredients in pharmaceutical compositions, optionally in combination with other antivirals, immunomodulators, antibiotics or vaccines.

HIV protease inhibitors

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Pyranyl aryl methyl benzoquinolinone M1 receptor positive allosteric modulators

The present invention is directed to pyranyl aryl methyl benzoquinazolinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Pyranyl aryl methyl benzoquinazolinone M1 receptor positive allosteric modulators

The present invention is directed to compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Quinolizidinone carboxamide  M1 receptor positive allosteric modulators

The present invention is directed to dihydrobenzoquinazilinone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Dihydrobenzoquinazolinone M1 receptor positive allosteric modulators

The present invention is directed to quinolinone-pyrazolone compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Pyridoquinazolinone M1 receptor positive allosteric modulators

The present invention is directed to compounds of formula (I) (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor.

Quinolizidinone M1 receptor positive allosteric modulators

The present invention is directed to spiropiperidine compounds of formula (I) which are M1 receptor positive allosteric modulators and that are useful in the treatment of diseases in which the M1 receptor is involved, such as Alzheimer's disease, schizophrenia, pain or sleep disorders. The invention is also directed to pharmaceutical compositions comprising the compounds, and to the use of the compounds and compositions in the treatment of diseases mediated by the M1 receptor. 

Growing community of inventors

Oreland, PA, United States of America

Ronald K Chang